iTc17 cells do not directly contribute to posttransplant tumor clearance. (A) CD8⁺YFP⁺ or CD8⁺YFP^neg T cells were isolated 7 days posttransplant (B6.IL-17^CreRosa26^eYFP→B6D2F1) and combined with WT.B6 T cell–depleted (TCD) BM for secondary transplant into lethally irradiated B6D2F1 recipients. Mice receiving TCD BM only were included as controls and all grafts supplemented with 1 × 10⁵ B6D2F1-derived BCR/ABL-NUP98/HOXA9 GFP⁺ CML leukemic cells before transplantation. (B) Representative flow cytometry analysis of leukemia progression and CD8⁺YFP⁺ T-cell expansion 14 days posttransplant. (C) CD8⁺YFP⁺ T cells were enumerated on d7, d14, and d21 posttransplant (± SEM, n = 10 mice/group; ****P < .0001, **P < .01). (D) Survival indices by Kaplan-Meier analysis and tumor growth posttransplant are shown. Data are pooled from 2 independent experiments (10 mice/group total; ***P < .001). (E) Representative images of blood smears collected 3 weeks posttransplant (Wright-Giemsa stain, original magnification ×200).